Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 3, 2001, Pages 1059-1066

  Pepinsky, R Blake ^a   Lepage, Doreen J ^a   Gill, Alan ^a   Chakraborty, Abhijit ^a   Vaidyanathan, Sujata ^a   Green, Marie ^a   Baker, Darren P ^a   Whalley, Eric ^a   Hochman, Paula S ^a   Martin, Pauline ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BETA1A INTERFERON; MACROGOL; NEOPTERIN;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; HUMAN; HUMAN CELL; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BETA 2-MICROGLOBULIN; BIOLOGICAL AVAILABILITY; CYTOPATHOGENIC EFFECT, VIRAL; DRUG ADMINISTRATION ROUTES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENCEPHALOMYOCARDITIS VIRUS; FEMALE; INTERFERON-BETA; INTERFERONS; MACACA MULATTA; METABOLIC CLEARANCE RATE; MICE; MOLECULAR WEIGHT; NEOPTERIN; PLAQUE ASSAY; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED LEW; TUMOR CELLS, CULTURED;

EID: 0035020761     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Alam J, Goelz S, Rioux P, Scaramuccii J, Jones W, McAllister A, Campion M and Rogge M (1997) Comparative pharmacokinetics and pharmacodynamic of two recombinant human interferon beta-1a (IFNβ-1a) products administered intramuscularly in healthy male and female volunteers. Pharm Res 14:546-549.
2. Baron S, Coppenhaver DH, Dianzani F, Fleischmann R, Hughes TK Jr, Klimpel GR, Niesel DW, Stanton GJ and Tyring SK (1992) Interferon: Principles and Medical Applications. The University of Texas Medical Branch at Galveston, Department of Microbiology, Galveston, TX.
3. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshim G, Chan S, Chu H, Mukku V, Canova-Davis E, et al. (1996) Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 271:21969-21977.
4. Delgado C, Francis GE and Fisher D (1992) The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9:249-304.
5. Delgado C, Francis GE, Malik F, Fisher D and Parkes V (1997) Polymer-derivatized proteins: analytical and preparative problems. Pharm Sci 3:59-66.
6. Derynck R, Remaut E, Saman E, Stanssens P, De Clercq E, Content J and Fiers W (1980) Expression of the human fibroblast interferon gene in Escherichia coli. Nature (Lond) 287:193-197.
7. Francis GE, Delgado C, Fisher D, Malik F and Agrawal AK (1996) Polyethylene glycol modification: applications in tumour targeting and cytokine therapy. J Drug Target 3:321-340.
8. Francis GE, Fisher D, Delgado C, Malik F, Gardiner A and Neale D (1998) PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol 68:1-18.
9. Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC (1989) Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. J Natl Cancer Inst 81:1061-1068.
10. Glue P, Fang JWS, Sabo R, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Jacobs S, Geraund JJ and Albrecht JK (1999) Peg-interferon-α2B: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data [Abstract] Hepatology 30 (Suppl):A189.
11. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP and the hepititis C intervention therapy group (2000) A dose finding study of pegylated interferon-alfa-2b and ribavirin in chronic hepatitis C. Hepatology 32: 647-653.
12. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al (1996) Intramuscular Interferon-Beta-1a for Disease Progression in Relapsing Multiple Sclerosis. Ann Neurol 39:285-294.
13. Jost LM, Kirkwood JM and Whiteside TL (1992) Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods 147:153-165.
14. Kagawa Y, Takasaki S, Utsumi J, Hosoi K, Shimizu H, Kochibe N and Kobata A (1988) Comparative study of the asparagine-linked sugar chains of natural human interferon-β1 and recombinant human interferon-β1 produced by three different mammalian cells. J Biol Chem 263:17508-17515.
15. Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN and Goelz SE (1997) The crystal structure of human interferon-β at 2.2 Å resolution. Proc Natl Acad Sci USA 94:11813-11818.
16. Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD and Katre NV (1988) Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 263:15064-15070.
17. Koumenis IL, Shahrokh Z, Leong S, Hsei V, Deforge L and Zapata G (2000) Modulating pharmacokinetics of an anti-interleukin-8 F(ab′)(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharm 198:83-95.
18. Mark DF, Lu SD, Creasey AA, Yamamoto R and Liu LS (1984) Site-specific mutagenesis of human fibroblast interferon gene. Proc Natl Acad Sci USA 81:5662-5666.
19. Nelson PA, Akselband Y, Dearborn SM, Al-Sabbagh A, Tian ZJ, Gonnella PA, Zamvil SS, Chen Y and Weiner HL (1996) Effect of oral beta interferon on subsequent immune responsiveness. Ann NY Acad Sci 778:145-155.
20. Peters M (1996) Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 23:909-916.
21. Runkel L, deDios C, Karpusas M, Betzenhauser M, Muldowney C, Zafari M, Benjamin CD, Miller S, Hochman PS and Whitty A (2000) Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity. Biochemistry 39:2538-2551.
22. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W and Goelz SE (1998) Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15:641-649.
23. Satoh Y, Kasama K, Kuwabara M, Yimin, Diao HY, Nakajima H, Kohanawa M and Minagawa T (1999) Suppression of late asthmatic response by low-dose oral administration of interferon-beta in the guinea pig model of asthma. J Interferon Cytokine Res 19:887-894.
24. Sen G and Lengyel P (1992) The interferon system: a bird's eye view of its biochemistry. J Biol Chem 267:5017-5020.
25. Stewart WE (1981) The Interferon System. Springer Verlag, New York.
26. The IFNβ Multiple Sclerosis Study Group (1993) Interferon-beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 43:655-661.
27. Tyring SK (1995) Interferons: biochemistry and mechanisms of action. Am J Obstet Gynecol 172:1350-1353.
28. Uze G, Lutfalla G and Mogensen KE (1995) Alpha and beta interferons and their friends and relations. J Interferon Cytokine Res 5:3-26.
29. Wang YS, Youngster S, Bausch J, Zhang R, McNemar C and Wyss DF (2000) Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 39:10634-10640.
30. Weinstock-Guttman B, Ransohoff RM, Kinkel RP and Rudick RA (1995) The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 37:7-13.